



GlaxoSmithKline Pharmaceuticals Limited  
GSK House, Dr. Annie Besant Road,  
Worli, Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

1<sup>st</sup> August 2025

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Subject: Media release: Q1 of 2025-26**

Please find enclosed a press release issued by the Company in respect of financial results for the quarter ended 30<sup>th</sup> June 2025 .

This is for your information and record.

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni

Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151



## **GlaxoSmithKline Pharmaceuticals Limited Delivers Sustained Profitability for Quarter Ended June 30, 2025; Continues to Invest in Key Portfolios**

**Mumbai, India** – GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the first quarter, ended June 30, 2025, showcasing its commitment to sustained profitability and continued investment across its key portfolios to drive future growth. While the quarter reported flat growth, the Company remains focused on strengthening its leadership position in key priority areas of anti-infectives, pain management and dermatology.

During the quarter, Revenue from Operations stood at INR 805 crores, with a Profit After Tax (PAT) of INR 205 crores. The General Medicines portfolio delivered strong external competitive performance in Q1, with key promoted brands achieving market share gains and above market growth [Source: IQVIA]. However, this performance was below anticipated levels, primarily due to external factors such as seasonal disruption, that affected overall results.

The Vaccines business continues to make good strides, reaffirming GSK's leadership in the self-pay private market for Paediatric vaccines. The Adult vaccines business is witnessing strong momentum, led by the continued adoption of Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted), as GSK accelerates efforts to expand adult immunisation in India.

The Company continues to accelerate momentum on driving significant innovation to deliver transformative healthcare solutions for patients in India. It is now preparing for the launch of its Oncology portfolio.

**Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited**, said, "GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies."

Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer.

**About GlaxoSmithKline Pharmaceuticals Limited:** GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit [GSK-India.com](https://www.gsk-india.com).

**Media Contact: *Communications and Government Affairs***

*Carson Dalton* – [carson.a.dalton@gsk.com](mailto:carson.a.dalton@gsk.com)

*Farah Bookwala* – [farah.a.bookwala@gsk.com](mailto:farah.a.bookwala@gsk.com)

\*The **Evolution Index** (EI) is a metric used to evaluate the performance of a product relative to the overall market growth.